Real-Time Analysis on Drug-Antibody Ratio of Antibody-Drug Conjugates for Synthesis, Process Optimization, and Quality Control

Drug-antibody ratio (DAR) of antibody-drug conjugates (ADCs) is important for their therapeutic efficacy and pharmacokinetics, therefore control on DAR in synthesis process is a key for ADC quality control. Although various analytical methods were reported, the real-time monitoring on DAR is still a challenge because time-consuming sample preparation is usually needed during the analysis. Antibody deglycosylation of ADC simplifies DAR measurement, however long-time PNGaseF digestion for deglycosylation hampers the real-time detection. Here, we report a rapid DAR analysis within 15 min by robust deglycosylation treatment and LC-MS detection that enables real-time DAR monitoring for optimization on ADC synthetic process. With this approach, we were able to screen suitable conjugation conditions efficiently and afford the ADCs with expected DARs. To the best of our knowledge, this is the first report on real-time DAR analysis of ADCs for conjugation optimization and quality control, compatible with random lysine-linked ADCs, glycosite-specific ADCs, and the complicated dual-payload ADCs.

[1]  Paul Polakis,et al.  Antibody Drug Conjugates for Cancer Therapy , 2016, Pharmacological Reviews.

[2]  Yelena Kovtun,et al.  Semisynthetic maytansine analogues for the targeted treatment of cancer. , 2006, Journal of medicinal chemistry.

[3]  P. Burke,et al.  Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody–Drug Conjugates , 2016, Molecular Cancer Therapeutics.

[4]  S. Bhakta,et al.  Engineering THIOMABs for site-specific conjugation of thiol-reactive linkers. , 2013, Methods in molecular biology.

[5]  Armin Ruf,et al.  Unique carbohydrate–carbohydrate interactions are required for high affinity binding between FcγRIII and antibodies lacking core fucose , 2011, Proceedings of the National Academy of Sciences.

[6]  Louisette Basa,et al.  Drug-to-antibody ratio (DAR) and drug load distribution by LC-ESI-MS. , 2013, Methods in molecular biology.

[7]  Peter G Schultz,et al.  Synthesis of site-specific antibody-drug conjugates using unnatural amino acids , 2012, Proceedings of the National Academy of Sciences.

[8]  Guodong Chen,et al.  Characterization of antibody-drug conjugates by mass spectrometry: advances and future trends. , 2016, Drug discovery today.

[9]  Yan Chen,et al.  Drug-to-antibody ratio (DAR) by UV/Vis spectroscopy. , 2013, Methods in molecular biology.

[10]  J Michael Ramsey,et al.  Characterization of Intact Antibody Drug Conjugate Variants Using Microfluidic Capillary Electrophoresis-Mass Spectrometry. , 2016, Analytical chemistry.

[11]  Alain Beck,et al.  Antibody-drug conjugate model fast characterization by LC-MS following IdeS proteolytic digestion , 2013, mAbs.

[12]  Wei Huang,et al.  One-pot N-glycosylation remodeling of IgG with non-natural sialylglycopeptides enables glycosite-specific and dual-payload antibody-drug conjugates. , 2016, Organic & biomolecular chemistry.

[13]  B. Tomczuk,et al.  Current ADC Linker Chemistry , 2015, Pharmaceutical Research.

[14]  Qun Zhou,et al.  Advances in the Development of Site-Specific Antibody-Drug Conjugation. , 2015, Anti-cancer agents in medicinal chemistry.

[15]  V. Monedero,et al.  Utilization of Natural Fucosylated Oligosaccharides by Three Novel α-l-Fucosidases from a Probiotic Lactobacillus casei Strain , 2010, Applied and Environmental Microbiology.

[16]  Kazuhiro Masuda,et al.  One-Step Conjugation Method for Site-Specific Antibody-Drug Conjugates through Reactive Cysteine-Engineered Antibodies. , 2016, Bioconjugate chemistry.

[17]  Carolyn R. Bertozzi,et al.  Copper-free click chemistry for dynamic in vivo imaging , 2007, Proceedings of the National Academy of Sciences.

[18]  F. V. van Delft,et al.  Chemoenzymatic Conjugation of Toxic Payloads to the Globally Conserved N-Glycan of Native mAbs Provides Homogeneous and Highly Efficacious Antibody-Drug Conjugates. , 2015, Bioconjugate chemistry.

[19]  Andreas Plückthun,et al.  The INNs and outs of antibody nonproprietary names , 2015, mAbs.

[20]  Bin Liu,et al.  Methods for site-specific drug conjugation to antibodies , 2013, mAbs.

[21]  Damon L. Meyer,et al.  Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate , 2004, Clinical Cancer Research.

[22]  Alain Van Dorsselaer,et al.  Innovative native MS methodologies for antibody drug conjugate characterization: High resolution native MS and IM-MS for average DAR and DAR distribution assessment. , 2014, Analytical chemistry.

[23]  Keyang Xu,et al.  Targeted drug delivery through the traceless release of tertiary and heteroaryl amines from antibody-drug conjugates. , 2016, Nature chemistry.

[24]  Qiang Yang,et al.  Glycosynthase Mutants of Endoglycosidase S2 Show Potent Transglycosylation Activity and Remarkably Relaxed Substrate Specificity for Antibody Glycosylation Remodeling* , 2016, The Journal of Biological Chemistry.

[25]  Bernhard Stump,et al.  Conjugation process development and scale-up. , 2013, Methods in molecular biology.

[26]  Robert C. Wolpert,et al.  A Review of the , 1985 .

[27]  Xiuru Li,et al.  Preparation of well-defined antibody-drug conjugates through glycan remodeling and strain-promoted azide-alkyne cycloadditions. , 2014, Angewandte Chemie.

[28]  Frank Loganzo,et al.  Natural Product Splicing Inhibitors: A New Class of Antibody-Drug Conjugate (ADC) Payloads. , 2016, Bioconjugate chemistry.

[29]  Surinder Kaur,et al.  Characterization of intact antibody-drug conjugates from plasma/serum in vivo by affinity capture capillary liquid chromatography-mass spectrometry. , 2011, Analytical biochemistry.

[30]  J. Ouyang,et al.  Drug-to-antibody ratio (DAR) and drug load distribution by hydrophobic interaction chromatography and reversed phase high-performance liquid chromatography. , 2013, Methods in molecular biology.

[31]  P. Drake,et al.  An emerging playbook for antibody-drug conjugates: lessons from the laboratory and clinic suggest a strategy for improving efficacy and safety. , 2015, Current opinion in chemical biology.

[32]  I. Sassoon,et al.  Antibody-drug conjugate (ADC) clinical pipeline: a review. , 2013, Methods in molecular biology.

[33]  Yang Feng,et al.  Site-specific antibody-drug conjugation through an engineered glycotransferase and a chemically reactive sugar , 2014, mAbs.

[34]  Matthew R. Levengood,et al.  Orthogonal Cysteine Protection Enables Homogeneous Multi‐Drug Antibody–Drug Conjugates , 2016, Angewandte Chemie.

[35]  Peter G Schultz,et al.  A general approach to site-specific antibody drug conjugates , 2014, Proceedings of the National Academy of Sciences.

[36]  Aditya A Wakankar,et al.  Analytical methods for physicochemical characterization of antibody drug conjugates , 2011, mAbs.

[37]  Wei Huang,et al.  Chemoenzymatic glycoengineering of intact IgG antibodies for gain of functions. , 2012, Journal of the American Chemical Society.

[38]  Serge Rudaz,et al.  Optimization of non-linear gradient in hydrophobic interaction chromatography for the analytical characterization of antibody-drug conjugates. , 2017, Journal of chromatography. A.

[39]  Laurent Ducry,et al.  Antibody-Drug Conjugates , 2013, Methods in Molecular Biology.

[40]  Fredrik Olsson,et al.  EndoS and EndoS2 hydrolyze Fc-glycans on therapeutic antibodies with different glycoform selectivity and can be used for rapid quantification of high-mannose glycans , 2015, Glycobiology.

[41]  Heather Donaghy,et al.  Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates , 2016, mAbs.

[42]  J. Ravetch,et al.  Fc-Receptor Interactions Regulate Both Cytotoxic and Immunomodulatory Therapeutic Antibody Effector Functions , 2015, Cancer Immunology Research.

[43]  P. Burke,et al.  Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index , 2015, Nature Biotechnology.